Summary Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors
Requires daily injection but produces significant body composition changes over 3 to 6 months
Patients should avoid areas that are tender, bruised, scarred, or have skin conditions
Pediatr Nephrol 23:209219 Dursun I, Poyrazoglu HM, Gunduz Z, Ulger H, Yklmaz A, Dusunsel R, Patroglu T, Gurgoze M (2009) The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease
This typically includes medical expenses (past and future), lost wages or earning capacity, pain and suffering, emotional distress, and in some cases, punitive damages